SOM 3355

Drug Profile

SOM 3355

Alternative Names: SOM3355

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator SOM Biotech
  • Class Small molecules
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Huntington's disease

Most Recent Events

  • 12 Apr 2016 SOM 3355 is available for licensing as of 12 Apr 2016. http://www.sombiotech.com
  • 12 Apr 2016 Clinical trials in Huntington's disease in Spain (PO) prior to April 2016 (SOM Biotech's pipeline, April 2016)
  • 12 Apr 2016 SOM Biotech plans a phase IIa trial for Huntington's disease in Spain (SOM Biotech's pipeline, April 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top